Loading…
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-87M | $-88M | $-68M | -39.2% | 105.0% | -7.3% |
| 2024 | $0M | $-95M | $-95M | $-80M | -77.0% | -95.3% | 7.5% |
| 2023 | $0M | $-88M | $-88M | $-76M | -45.6% | -726.5% | 4.4% |
| 2022 | $-0M | $-84M | $-85M | $-63M | -45.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | -0.07 | 0.43 | 0.02 | 0.04 |
| Operating Revenue | - | -0.07 | 0.43 | 0.02 | 0.04 |
| Operating Expense | - | 87.67 | 83.94 | 103.19 | 94.53 |
| Research And Development | - | 70.54 | 65.80 | 82.23 | 66.43 |
| Selling General And Administration | - | 17.13 | 18.14 | 20.97 | 28.10 |
| Total Expenses | - | 87.67 | 83.94 | 103.19 | 94.53 |
| Operating Income | - | -87.74 | -83.51 | -103.17 | -94.49 |
| Total Operating Income As Reported | - | -87.74 | -95.93 | -103.17 | -94.49 |
| EBITDA | - | -84.41 | -87.94 | -94.81 | -87.03 |
| Normalized EBITDA | - | -84.41 | -75.52 | -94.81 | -87.03 |
| EBIT | - | -84.90 | -88.41 | -95.05 | -87.14 |
| Interest Income | - | 2.87 | 7.35 | 8.07 | 7.54 |
| Interest Expense | - | 0.01 | 0.04 | 0.01 | 1.64 |
| Net Interest Income | - | 2.86 | 7.32 | 8.06 | 5.90 |
| Other Non Operating Income Expenses | - | -0.03 | 0.17 | 0.05 | -0.19 |
| Other Income Expense | - | -0.03 | -12.25 | 0.05 | -0.19 |
| Interest Income Non Operating | - | 2.87 | 7.35 | 8.07 | 7.54 |
| Interest Expense Non Operating | - | 0.01 | 0.04 | 0.01 | 1.64 |
| Net Non Operating Interest Income Expense | - | 2.86 | 7.32 | 8.06 | 5.90 |
| Pretax Income | - | -84.91 | -88.45 | -95.06 | -88.77 |
| Tax Provision | - | -0.20 | 0 | 0 | -0.68 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Net Income From Continuing And Discontinued Operation | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Net Income From Continuing Operation Net Minority Interest | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Net Income | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Net Income Common Stockholders | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Net Income Including Noncontrolling Interests | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Normalized Income | - | -84.71 | -76.03 | -95.06 | -88.09 |
| Diluted NI Availto Com Stockholders | - | -84.71 | -88.45 | -95.06 | -88.09 |
| Basic Average Shares | - | 46.93 | 53.25 | 71 | 88.10 |
| Diluted Average Shares | - | 46.93 | 53.25 | 71 | 88.10 |
| Reconciled Depreciation | - | 0.49 | 0.48 | 0.24 | 0.11 |
| Total Unusual Items | -11.37 | 0 | -12.42 | 0 | - |
| Total Unusual Items Excluding Goodwill | -11.37 | 0 | -12.42 | 0 | - |
| Special Income Charges | -11.37 | 0 | -12.42 | 0 | - |
| Impairment Of Capital Assets | 11.37 | 0 | 12.42 | 0 | - |
| General And Administrative Expense | - | 17.13 | 18.14 | 20.97 | 28.10 |
| Other Gand A | - | 17.13 | 18.14 | 20.97 | 28.10 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Altimmune, Inc.this co. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Rigel Pharmaceuticals, Inc. | RIGL | $560M | 1.52 | 1.43 | 93.8% | 4.35 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $560M | 23.30 |
| - |
| - |
| - |
| - |
| -2.14 |
| -9.2% |
| 9.00 |
| Cytek Biosciences, Inc. | CTKB | $559M | -8.40 | 1.64 | -19.5% | -28.29 |
| Cerus Corporation | CERS | $559M | - | 8.70 | -24.3% | - |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Peer Median | - | 1.52 | 1.92 | -7.3% | 4.35 | |